Dehydroepiandrosterone levels vary according as heart failure condition in patients with idiopathic dilated cardiomyopathy.

Department of Cardiovascular Medicine, Kumamoto University School of Medicine, Kumamoto, Japan
International journal of cardiology (Impact Factor: 6.18). 05/2008; 125(2):277-9. DOI: 10.1016/j.ijcard.2007.08.115
Source: PubMed

ABSTRACT The secretion of dehydroepiandrosterone sulfate (DHEAS) decreases with age, and the incidence of heart failure rises in the elderly population. We measured plasma DHEAS levels in 50 male patients (mean 66.7+/-9.1 years old) with congestive heart failure due to idiopathic dilated cardiomyopathy before and after treatment. The study included 50 age-matched control subjects with coronary spastic angina (mean 65.5+/-8.8 years old). DHEAS levels were significantly lower in patients with congestive heart failure than in controls (82.2+/-9.9 vs. 122.7+/-18.6 microg/dL, respectively, p<0.01), whereas there was no difference in cortisol levels between the 2 groups. After 3 months of treatment, NYHA functional class improved in all patients, and DHEAS levels increased (from 82.2+/-9.9 to 106.2+/-21.1 microg/dL, p<0.01). DHEAS levels vary according as heart failure condition in patients with idiopathic dilated cardiomyopathy.

  • [Show abstract] [Hide abstract]
    ABSTRACT: This article provides an overview of alcoholic dilated cardiomyopathy. It aims to increase awareness of the condition among nurses, and help in early diagnosis and appropriate treatment referrals. The key message is that all patients with alcoholic dilated cardiomyopathy should be advised and assisted to stop drinking alcohol.
    Nursing standard: official newspaper of the Royal College of Nursing 01/2011; 22(38):42-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiac cachexia (CC) affects a large proportion of patients with chronic heart failure, a major public health issue in western countries. The pathophysiology of cardiac cachexia is complex and multifactorial, resulting from several factors interacting in a complex system with metabolic, immune and neurohormonal consequences, triggered to protect the heart and the circulation from damage. Despite the adverse clinical effects, CC diagnosis is not straightforward and has not specifically been targeted, with therapeutic strategies only comprising interventions with appetite stimulants, and anti-inflammatory substances. Here we review the molecular pathways underlying CC-related muscle wasting aiming to provide clues for the definition of CC-specific biomarkers and for the development of drugs that prevent and/or counteract muscle impairment, which will certainly impact the management of cardiovascular disorders.
    Clinical biochemistry 10/2013; · 2.02 Impact Factor